Related changes
Jump to navigation
Jump to search
Enter a page name to see changes on pages linked to or from that page. (To see members of a category, enter Category:Name of category). Changes to pages on your Watchlist are in bold.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
30 April 2024
|
|
N 18:58 | Isosulfan Blue 2 changes history +5,962 [Alara E. Dagsali (2×)] | |||
|
|
18:58 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
| N |
|
18:57 (cur | prev) +5,959 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Lymphazurin |aOrAn=a |indicationType=treatment |indication=Isosulfan blue injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therape...") | |||
|
|
N 18:47 | Ibuprofen Lysine 2 changes history +15,666 [Alara E. Dagsali (2×)] | |||
|
|
18:47 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
| N |
|
18:46 (cur | prev) +15,663 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=Ibuprofen lysine |aOrAn=a |indicationType=treatment |indication=Ibuprofen Lysine is indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective. The clinical trial was conduc...") | |||
|
|
N 18:28 | Prussian blue 2 changes history +14,070 [Alara E. Dagsali (2×)] | |||
|
|
18:28 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
| N |
|
18:27 (cur | prev) +14,067 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |drugClass=RADIOGARDASE |indicationType=treatment |indication=Radiogardase is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination |adverseReactions=Most common adverse reaction (incidence >24%) was constipation Constipation was reported in 10 (24%) of 42 patients treated with R...") | |||
|
|
N 18:15 | Botulism Antitoxin 2 changes history +18,011 [Alara E. Dagsali (2×)] | |||
|
|
18:15 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
| N |
|
18:14 (cur | prev) +18,008 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=BAT |aOrAn=a |indicationType=treatment |indication=BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] is a mixture of immune globulin fragments indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients. |adverseReactions=The most common adverse reactions obse...") | |||
29 April 2024
|
|
N 15:25 | Trastuzumab emtansine 2 changes history +40,575 [Alara E. Dagsali (2×)] | |||
|
|
15:25 (cur | prev) −35 Alara E. Dagsali talk contribs | ||||
| N |
|
15:23 (cur | prev) +40,610 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=AlaraE.Dagsali |genericName=ado-trastuzumab emtansine |indicationType=treatment |indication=the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. the adjuvant treatment...") | |||
25 April 2024
| 22:45 | Norelgestromin diffhist +3 Alara E. Dagsali talk contribs | ||||
|
|
22:45 | Tranexamic 6 changes history +1 [Alara E. Dagsali (6×)] | |||
|
|
22:45 (cur | prev) +11 Alara E. Dagsali talk contribs | ||||
|
|
22:44 (cur | prev) −11 Alara E. Dagsali talk contribs | ||||
|
|
22:41 (cur | prev) +2 Alara E. Dagsali talk contribs | ||||
|
|
22:41 (cur | prev) −1 Alara E. Dagsali talk contribs | ||||
|
|
22:40 (cur | prev) +14 Alara E. Dagsali talk contribs Tag: Manual revert | ||||
|
|
22:39 (cur | prev) −14 Alara E. Dagsali talk contribs Tag: Manual revert | ||||
24 April 2024
|
|
N 21:26 | Tranexamic 7 changes history +23,022 [Alara E. Dagsali (7×)] | |||
|
|
21:26 (cur | prev) +14 Alara E. Dagsali talk contribs Tag: Manual revert | ||||
|
|
21:26 (cur | prev) −11 Alara E. Dagsali talk contribs | ||||
|
|
21:25 (cur | prev) −2 Alara E. Dagsali talk contribs Tag: Manual revert | ||||
|
|
21:23 (cur | prev) −1 Alara E. Dagsali talk contribs | ||||
|
|
21:23 (cur | prev) +3 Alara E. Dagsali talk contribs Tag: Visual edit: Switched | ||||
|
|
21:22 (cur | prev) −1 Alara E. Dagsali talk contribs | ||||
| N |
|
21:14 (cur | prev) +23,020 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Tranexamic |aOrAn=a |drugClass=hemophilia drug |indicationType=prevention |indication=Tranexamic acid injection is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. |adverseReactions=Thromboembolic Risk Seizures Hypersensitivity Reactions Visual Disturbances Dizzines...") | |||